Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
| 対象疾患 | FSGS |
|---|---|
| 相 | 第3相 |
| スポンサー | University of Colorado, Denver |
| ステータス | 完了 |
| 参加者数 | 15 名 |
| 介入（薬剤） | Acthar |
| 開始日 | 2019年2月1日 |
| 完了日 | 2024年6月6日 |
| 結果公開日 | 2020年3月24日 |
概要
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
Rate of Recurrence of FSGS as Seen in Renal Transplant Biopsies Proteinuria
| One Arm | 14 Participants |
|---|
Rate of Recurrence of Proteinuria
| One Arm | 3 Participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoieti — GlaxoSmithKline
- Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
- Bone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine
- Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients — The University of Texas at Arlington
- Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver F — Genfit
- High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis. — University of Florida